Pharmicell’s next generation stem cell therapy base technology is published in ‘an international academic journal’
Pharmicell(005690, co-headed by Kim, Hyeon-Soo and Kim, Seong-Rae) has succeeded in acquiring base technology for the development of next generation stem cell therapy.
Pharmicell’s research findings on stem cell delivery system co-worked by the research team of the University of Utah are issued in ‘Molecular Therapy’, the official journal of American Society of Gene & Cell Therapy.
The article is titled ‘Human Mesenchymal Stem Cell Delivery System Modulates Ischemic Cardiac Remodeling With an Increase of Coronary Artery Blood Flow’.
The research shows MSC-loaded PPP(Porous PLGA/PEI1.8, 3D scaffold) injected into animal’s cardiac muscle leads to increase in persistence of cells and effectively recovering heart damage.
Pharmicell signed an MOU with the University of Utah to jointly develop an improved delivery system to send stem cell cures to affected area of a patient through the continued researches.
Last year, study results that imply the possibility of developing PPP to increase stem cell’s survival and in vivo engraftment rates were published and this time, an improved PPP injected into animals is applied to the clinical research.
“The research allowed us to successfully acquire base technology for developing the next generation stem cell therapy and apply it to clinical trials ahead. The technology will also be applied to other incurable diseases such as brain/nerve disorders and liver cirrhosis,” said Kim, Hyeon-Soo.
He added, “The next generation stem cell therapy will significantly shorten ex vivo expansion time to reduce production costs and provide effective treatments for damaged tissues compared to the existing therapy.”